1 Ocak 2018 Dergi makalesi Açık Erişim

Coban, Ozlem; Degim, Zelihagul

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/34767</identifier>
  <creators>
    <creator>
      <creatorName>Coban, Ozlem</creatorName>
      <givenName>Ozlem</givenName>
      <familyName>Coban</familyName>
      <affiliation>Karadeniz Tech Univ, Fac Pharm, Dept Pharmaceut Technol, Trabzon, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Degim, Zelihagul</creatorName>
      <givenName>Zelihagul</givenName>
      <familyName>Degim</familyName>
      <affiliation>Biruni Univ, Dept Pharmaceut Technol, Fac Pharm, Istanbul, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Development Of Nanocochleates Containing Erlotinib Hcl And Dexketoprofen Trometamol And Evaluation Of In Vitro Characteristic Properties</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2018</publicationYear>
  <dates>
    <date dateType="Issued">2018-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/34767</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.4274/tjps.83803</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Objectives: Erlotinib HCl is a tyrosine kinase receptor inhibitor and an anticancer agent that was first approved by the FDA in 2004 for treatment of non-small-cell lung cancer and pancreatic cancer. Dexketoprofen trometamol is a NSAID, but recent studies showed that dexketoprofen trometamol also had an effect in carcinoma due to its inhibitor effects on prostaglandins. The combination of dexketoprofen and anti-cancer agents reduces pain caused by cancer by diminishing the tumors pressure, which causes necrosis; it also lowers the poor prognosis of cancer. Combination therapy will make life easier for patients, considering drug administration and dosing. Nanocochleates are new drug delivery systems that have not been examined as much as liposomes, but they have more advantages than liposomes.</description>
  </descriptions>
</resource>